196 related articles for article (PubMed ID: 22986144)
1. Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study.
Alberts DS; Blessing JA; Landrum LM; Warshal DP; Martin LP; Rose SL; Bonebrake AJ; Ramondetta LM
Gynecol Oncol; 2012 Dec; 127(3):451-5. PubMed ID: 22986144
[TBL] [Abstract][Full Text] [Related]
2. A phase II, multicenter, single-arm study of tri-weekly low-dose nanoparticle albumin-bound paclitaxel chemotherapy for patients with metastatic or recurrent breast cancer.
Yamamoto S; Maeda N; Nagashima Y; Kubo H; Sato Y; Matsui H; Inoue Y; Shindo Y; Kanekiyo S; Sakamoto K; Suzuki N; Takeda S; Ueno T; Yoshino S; Hazama S; Oka M; Nagano H
Breast Cancer; 2017 Nov; 24(6):783-789. PubMed ID: 28439763
[TBL] [Abstract][Full Text] [Related]
3. Nab-paclitaxel plus platinum versus paclitaxel plus platinum as first-line therapy in patients with metastatic or recurrent cervical cancer.
Liu Y; Fang SS; Zhao RS; Liu B; Jin YQ; Li Q
J Cancer Res Clin Oncol; 2024 Jun; 150(6):321. PubMed ID: 38914827
[TBL] [Abstract][Full Text] [Related]
4. Treatment of recurrent and platinum-refractory stage IV non-small cell lung cancer with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as a single agent.
Saxena A; Schneider BJ; Christos PJ; Audibert LF; Cagney JM; Scheff RJ
Med Oncol; 2016 Feb; 33(2):13. PubMed ID: 26749586
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer.
Sasaki Y; Nishina T; Yasui H; Goto M; Muro K; Tsuji A; Koizumi W; Toh Y; Hara T; Miyata Y
Cancer Sci; 2014 Jul; 105(7):812-7. PubMed ID: 24716542
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma.
Huang Y; Liang W; Yang Y; Zhao L; Zhao H; Wu X; Zhao Y; Zhang Y; Zhang L
BMC Cancer; 2016 Jul; 16():464. PubMed ID: 27411683
[TBL] [Abstract][Full Text] [Related]
7. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study.
Coleman RL; Brady WE; McMeekin DS; Rose PG; Soper JT; Lentz SS; Hoffman JS; Shahin MS
Gynecol Oncol; 2011 Jul; 122(1):111-5. PubMed ID: 21497382
[TBL] [Abstract][Full Text] [Related]
8. A phase 2 study of nanoparticle albumin-bound paclitaxel plus nedaplatin for patients with advanced, recurrent, or metastatic cervical carcinoma.
Li Y; Zeng J; Huang M; An J; Bai P; Wu L; Zhang R
Cancer; 2017 Feb; 123(3):420-425. PubMed ID: 27696395
[TBL] [Abstract][Full Text] [Related]
9. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W
Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157
[TBL] [Abstract][Full Text] [Related]
10. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
Teneriello MG; Tseng PC; Crozier M; Encarnacion C; Hancock K; Messing MJ; Boehm KA; Williams A; Asmar L
J Clin Oncol; 2009 Mar; 27(9):1426-31. PubMed ID: 19224848
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: a New York Cancer Consortium Study.
Kuo DY; Blank SV; Christos PJ; Kim M; Caputo TA; Pothuri B; Hershman D; Goldman N; Ivy PS; Runowicz CD; Muggia F; Goldberg GL; Einstein MH
Gynecol Oncol; 2010 Mar; 116(3):442-6. PubMed ID: 19931137
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030).
Grau JF; Farinas-Madrid L; Oaknin A
Int J Gynecol Cancer; 2020 Jan; 30(1):139-143. PubMed ID: 31645423
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
Palumbo R; Sottotetti F; Trifirò G; Piazza E; Ferzi A; Gambaro A; Spinapolice EG; Pozzi E; Tagliaferri B; Teragni C; Bernardo A
Drug Des Devel Ther; 2015; 9():2189-99. PubMed ID: 25931813
[TBL] [Abstract][Full Text] [Related]
14. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group study.
Thigpen JT; Blessing JA; Olt G; Lentz SS; Bell J
Gynecol Oncol; 2003 Sep; 90(3):581-6. PubMed ID: 13678728
[TBL] [Abstract][Full Text] [Related]
16. First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix--a phase II study.
Piver MS; Ghamande SA; Eltabbakh GH; O'Neill-Coppola C
Gynecol Oncol; 1999 Dec; 75(3):334-7. PubMed ID: 10600285
[TBL] [Abstract][Full Text] [Related]
17. A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer.
Ciruelos E; Apellániz-Ruiz M; Cantos B; Martinez-Jáñez N; Bueno-Muiño C; Echarri MJ; Enrech S; Guerra JA; Manso L; Pascual T; Dominguez C; Gonzalo JF; Sanz JL; Rodriguez-Antona C; Sepúlveda JM
Oncologist; 2019 Nov; 24(11):e1024-e1033. PubMed ID: 31023863
[TBL] [Abstract][Full Text] [Related]
18. A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer.
Kitagawa R; Katsumata N; Ando M; Shimizu C; Fujiwara Y; Yoshikawa H; Satoh T; Nakanishi T; Ushijima K; Kamura T
Gynecol Oncol; 2012 May; 125(2):307-11. PubMed ID: 22333993
[TBL] [Abstract][Full Text] [Related]
19. Phase II multi-institutional prospective trial of nab-paclitaxel as second-line chemotherapy for advanced gastric cancer refractory to fluoropyrimidine with modified dose reduction criteria (CCOG1303).
Kobayashi D; Mochizuki Y; Torii K; Takeda S; Kawase Y; Ishigure K; Teramoto H; Ando M; Kodera Y
Int J Clin Oncol; 2020 Oct; 25(10):1793-1799. PubMed ID: 32567012
[TBL] [Abstract][Full Text] [Related]
20. Combination of ifosfamide, paclitaxel, and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: a phase II study of the Hellenic Cooperative Oncology Group.
Dimopoulos MA; Papadimitriou CA; Sarris K; Aravantinos G; Kalofonos C; Gika D; Gourgoulis GM; Efstathiou E; Skarlos D; Bafaloukos D
Gynecol Oncol; 2002 Jun; 85(3):476-82. PubMed ID: 12051877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
